Alinity m MPXV Assay (EUA)*

*For Use Under an Emergency Use Authorization (EUA) Only. For In Vitro Diagnostic Use. Rx Only.


MonkeypoxAssay_ProductImage_US_1200px.png


Abbott's Pandemic Response In Action

ALINITY m MPXV IS THE FIRST COMMERCIAL TEST KIT TO BE emergency use AUTHORIZED BY THE FDA FOR THE DETECTION OF MONKEYPOX.

Harness the power of ReadiFlex to easily manage varying testing volumes and consolidation of assays on Alinity m.

ReadiFlex on Alinity m provides the flexibility to integrate EUA monkeypox virus (MPXV) testing into your established workflows and adapt to varying testing volumes, while maintaining your regular service commitments.

ALINITY m DELIVERS OPERATIONAL EFFICIENCIES ACROSS HEALTHCARE
  • Alinity m is a continuous and random-access molecular analyzer with a time-to-first result of less than 115 minutes enabling you to eliminate batching procedures and improve laboratory workflow.
  • All steps of the Alinity m MPXV (EUA) assay procedure are performed automatically by the Alinity m system with no intermediate processing or transfer steps performed by the user. 

UNIQUE ASSAY DESIGN DELIVERS CONFIDENCE IN RESULTS

  • Dual target assay design for current and future viral evolution
  • Internal control for assessment of amplification efficiency and potential PCR inhibition
  • Cellular control for assessment of sample adequacy to potentially reduce patient recall due to inadequate sample collection

The Alinity m MPXV assay is a real-time polymerase chain reaction (PCR) test intended for the qualitative detection of DNA from monkeypox virus in human skin lesion material specimens from individuals suspected of monkeypox infection by their healthcare provider.

icon-pdf.png



VIEW ORDERING INFORMATION 
Product Details
 
INTENDED USE

The Alinity m MPXV assay is a real-time polymerase chain reaction (PCR) test intended for the qualitative detection of DNA from monkeypox virus (clade I/II) in human lesion swab specimens (i.e., swabs of acute pustular or vesicular rash) in viral transport media (VTM) from individuals suspected of monkeypox infection by their healthcare provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate or high complexity tests.

Results are for the identification of monkeypox virus (clade I/II) DNA, which is generally detectable in human pustular or vesicular lesion specimens during the acute phase of infection. Positive results are indicative of the presence of monkeypox virus (clade I/II) DNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Negative results obtained with this device do not preclude monkeypox virus (clade I/II) infection and should not be used as the sole basis for treatment or other patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

Laboratories within the United States and its territories are required to report test results to the appropriate public health authorities.

The Alinity m MPXV assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of PCR and in vitro diagnostic procedures.

The Alinity m MPXV assay is only for use under the Food and Drug Administration’s Emergency Use Authorization.

LIMITATIONS OF THE PROCEDURE
  • For use under an Emergency Use Authorization only.
  • This assay is for in vitro diagnostic use under FDA Emergency Use Authorization only.
  • Use of the Alinity m MPXV assay is limited to personnel who have been trained in the procedures of a molecular diagnostic assay and the Alinity m System.
  • Laboratories are required to report all results to the appropriate public health authorities.
  • The instruments and assay procedures reduce the risk of contamination by amplification product. However, nucleic acid contamination from the positive controls or specimens must be controlled by good laboratory practice and careful adherence to the procedures specified in the package insert.
  • Optimal performance of this test requires appropriate specimen collection and handling (refer to the SPECIMEN TYPE, STORAGE, AND PREPARATION FOR ANALYSIS section of the package insert).
  • This assay does not detect variola virus (smallpox virus).
  • While monkeypox virus clade II is the only member of the Orthopoxvirus genus known to be circulating among humans in the US at this time, a positive result most likely represents the presence of monkeypox virus clade II, although there is a small possibility that this result could represent the presence of monkeypox virus clade I. If clinical concern for such an infection exists, healthcare providers should contact the CDC and their local public health authorities for guidance.
  • Performance of the assay has been evaluated using contrived clinical lesion swab specimens. Clinical Performance with natural clinical lesion specimens has not been established.
  • The assay is indicated for testing of lesion swab specimens. Performance for other specimen types has not been established.
  • Performance of the test has only been established in lesion swabs collected in VTM. Performance of the test has not been evaluated for dry swabs or for lesion swabs collected in other transport media types.
  • A specimen with a result of “MPXV Negative” does not preclude monkeypox virus infection and should not be used as the sole basis for treatment or other patient management decisions. Collection of multiple specimens (and specimens collected at different time points) from the same patient may be necessary to detect the virus.
  • Detection of monkeypox virus DNA may be affected by sample collection methods (eg, if a specimen is improperly collected, transported, or handled), patient factors (eg, presence, type, and duration of symptoms), and/or stage of infection (eg, if collected too early or too late in the course of illness).
  • False-negative results may arise from degradation of the viral DNA during storage and transport of the specimens.
  • Interfering substances studies have not been performed for this assay. The assay uses conventional well-established nucleic acid extraction methods used for other similar assays. Interference from common endogenous substances is not anticipated.
  • The impacts of specific vaccines, antiviral therapeutics, antibiotics, chemotherapeutic or immunosuppressant drugs on the performance of this test have not been evaluated.
  • As with any molecular test, mutations within the target regions of Alinity m MPXV assay could affect primer and/or probe binding resulting in failure to detect the presence of virus.
  • The clinical performance has not been established with all circulating variants but is anticipated to be reflective of the prevalent variants in circulation at the time and location of the clinical evaluation. Performance at the time of testing may vary depending on the variants circulating, including newly emerging strains of monkeypox virus and their prevalence, which change over time.
  • Results should be interpreted by a trained professional in conjunction with the patient’s history and clinical signs and symptoms, and epidemiological risk factors.
    For in vitro diagnostic use under the FDA EMERGENCY USE AUTHORIZATION
    • For use under an Emergency Use Authorization
    • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; use by laboratories certified under CLIA, to perform moderate or high complexity tests.
    • This product has been authorized only for the detection of nucleic acid from monkeypox virus, not for any other viruses or pathogens; and
    • The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of monkeypox virus, including in vitro diagnostics that detect and/or diagnose infection with non-variola Orthopoxvirus, under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b) (1), unless the declaration is terminated or authorization is revoked sooner.
    • Do not use beyond expiration date.
    • For Prescription Use Only.
    specifications
     

     

    ABBOTT ALINITY m MONKEYPOX ASSAY (EUA) Specifications1-4
    Technology Real-time PCR
    Time to First Result < 115 minutes
    Throughput Up to 1,080 samples in 24 hours*
    Probe Design Single-stranded probes
    Target Region Dual Target: B7R and J2R
    Result Reporting MPXV Negative / MPXV Positive XX.XX CN
    Sample Types Human lesion swab specimens collected in VTM
    Sample Input Volume 400 μL
    Internal Control (IC) Exogenous plasmid DNA
    Cellular Control (CC) Human ß-globin gene (DNA)

    *Number of actual samples per 24-hour period may vary based on laboratory practice and workflow.
    1. Abbott. Alinity m MPXV AMP Kit Package Insert 53-608429/R1.
    2. Abbott. Alinity m MPXV CTRL Kit Package Insert 53-608428/R1.
    3. Abbott Molecular. Data on File.
    4. Abbott. Alinity m Operations Manual 54-605001/R10.
     
     
    Related Product
     

    AMPLIFY YOUR IMPACT WITH ALINITY m

    Alinity m is a fully integrated and automated molecular diagnostics analyzer that uses ReadiFlex technology to deliver the next level of flexibility and efficiency to your lab. 

    FLEXIBILITY: True random access to perform any test, any time
    TURNAROUND TIME: <115 minutes time to first result
    THROUGHPUT: 300 samples in ~8 hours

    Learn More

    alinity_m_right_no_shadow_edited2_thumbnail.png

    Ordering Info

    You are about to exit the Abbott family of websites for a 3rd party website

    Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

    Do you wish to continue and exit this website?

    Yes No

    You are about to enter an Abbott country or region specific website.

    Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

    Do you wish to continue and enter this website?

    Yes No